Albireo leads the way with rare disease candidate

25 January 2021
albireo_large

Boston, USA-based Albireo Pharma (Nasdaq: ALBO) - a spinoff of UK-based AstraZeneca (LSE: AZN) - is moving ahead with the regulatory process for odevixibat.

Albireo has submitted for marketing approval for the treatment of pruritus in people with progressive familial intrahepatic cholestasis (PFIC), a rare and serious disorder that causes progressive, life-threatening liver disease.

The US Food and Drug Administration has granted Priority Review designation to the firm’s submission and is expected to provide a decision by July 20, 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology